Asia Pacific Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI107929

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 6.9% from 2023 to 2030
Unit	Value (USD Billion)
Segmentation	Drug Class; Route of Administration; Distribution Channel; and Country/Sub-Region
By Drug Class	Immunomodulators Immunosuppressants Interferons Others
By Route of Administration	Oral Injection Intramuscular Subcutaneous Intravenous
By Distribution Channel	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Country/Sub-Region	China India Japan Australia South East Asia Rest of Asia Pacific